Literature DB >> 17607777

The viral genetic background determines the outcome of coxsackievirus B3 infection in outbred NMRI mice.

M Schmidtke1, I Merkle, K Klingel, E Hammerschmidt, A E Zautner, P Wutzler.   

Abstract

The reasons for the different outcome of coxsackievirus B3 (CVB3)-induced heart disease in humans are not well understood. Since there are no experimental data on the course of disease after infection with genetically different CVB3 in a natural variable population until now, we studied the outcome of virus infection in outbred NMRI mice after inoculation of genetically different CVB3 variants. Adult male mice were inoculated with seven closely related CVB3 variants. The histopathological changes of heart and pancreas tissue, antibody induction, virus titers, and persistence of viral positive- as well as negative-strand RNA in spleen and heart tissue were compared at day 7 or day 28 after infection to detect prerequisites and predictive factors for chronic myocarditis. Six CVB3 variants infected NMRI mice. CVB3 infection (i) did not induce detectable myocardial injury, (ii) caused signs of healing up acute myocarditis or (iii) ongoing chronic myocarditis. Neither IgG antibody responses nor the extent of destruction of exocrine pancreatic tissue or viral RNA load in spleen did correlate with myocardial histopathology. In contrast, a high persistent viral RNA load in heart tissue specimens was characteristic for mice developing chronic myocarditis. The results of the present study corroborate high viral load in the acute stage of myocarditis and high amounts of persisting CVB3 RNA in heart tissue as predictive marker of chronic myocarditis. The outcome of CVB3-induced heart disease in outbred NMRI mice depends strongly on the viral genetic background. In particular an important role of viral capsid proteins is suggested.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17607777     DOI: 10.1002/jmv.20933

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Mapping of a quantitative trait locus controlling susceptibility to Coxsackievirus B3-induced viral hepatitis.

Authors:  S A Wiltshire; J Marton; G A Leiva-Torres; S M Vidal
Journal:  Genes Immun       Date:  2015-03-19       Impact factor: 2.676

2.  Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line.

Authors:  Sandra Pinkert; Karin Klingel; Vanessa Lindig; Andrea Dörner; Heinz Zeichhardt; O Brad Spiller; Henry Fechner
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

Review 3.  Coxsackievirus B3-Its Potential as an Oncolytic Virus.

Authors:  Anja Geisler; Ahmet Hazini; Lisanne Heimann; Jens Kurreck; Henry Fechner
Journal:  Viruses       Date:  2021-04-21       Impact factor: 5.048

4.  Non-diarrhoeal increased frequency of bowel movements (IFoBM-ND): enterovirus association with the symptoms in children.

Authors:  C Durga Rao; P P Maiya; M Ananda Babu
Journal:  BMJ Open Gastroenterol       Date:  2015-02-06

5.  Exploration of Analgesia with Tramadol in the Coxsackievirus B3 Myocarditis Mouse Model.

Authors:  Sandra Pinkert; Meike Kespohl; Nicolas Kelm; Ziya Kaya; Arnd Heuser; Karin Klingel; Antje Beling
Journal:  Viruses       Date:  2021-06-24       Impact factor: 5.048

6.  Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H.

Authors:  Ahmet Hazini; Babette Dieringer; Karin Klingel; Markian Pryshliak; Anja Geisler; Dennis Kobelt; Ole Daberkow; Jens Kurreck; Sophie van Linthout; Henry Fechner
Journal:  Viruses       Date:  2021-09-24       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.